Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The AML19 trial looks to build upon previous trials in AML. It is known that the condition can present with one of two subtypes, and this is taken into account in the trial design. In the majority of patients (those who do not have the APL-subtype), the trial looks to refine the current standard of care (which is a combination of drugs called DA) by asking a number of questions: 1. To compare two drug combinations (Daunorubicin/Ara-C – DA vs Fludarabine/Ara-C/G-CSF/Idarubicin – FLAG-Ida) to see which gives better survival 2. To identify the best way of giving the drug Mylotarg in addition to chemotherapy – either at a single dose of 3mg/m2 or in 2 doses of either 3mg/m2 or 5mg whichever is smaller. (This randomisation will only be available to patients who are suitable to receive Mylotarg). 3. In patients who receive FLAG-Ida, to work out the optimal number of courses of treatment. In particular, how much if any consolidation treatment with Ara-C is required – a randomisation bet
Critère d'inclusion
- Acute Myeloid Leukaemia High Risk Myelodysplastic Syndrome